NASDAQ: SRRKScholar Rock Holding Corp Stock
$47.33+0.38 (+0.81%)
Updated Jun 18, 2026
SRRK Price
$47.33
Fair Value Price
$1.87
Market Cap
$5.67B
52 Week Low
$27.07
52 Week High
$52.19
P/E
-13.68x
P/B
20.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$408.73M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.94
Operating Cash Flow
-$303M
Beta
1.05
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SRRK Overview
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SRRK's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SRRK
Ranked#384 of 465
Ranked#384 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important SRRK news, forecast changes, insider trades & much more!
SRRK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SRRK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SRRK ($47.33) is overvalued by 2,429.59% relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SRRK ($47.33) is not significantly undervalued (2,429.59%) relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SRRK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SRRK due diligence checks available for Premium users.
Valuation
SRRK fair value
Fair Value of SRRK stock based on Discounted Cash Flow (DCF)
Price
$47.33
Fair Value
$1.87
Overvalued by
2,429.59%
SRRK ($47.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SRRK ($47.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SRRK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SRRK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.68x
Industry
15.77x
Market
9.47x
SRRK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
20.55x
Industry
4.95x
SRRK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SRRK's financial health
Profit margin
Revenue
$0.0
Net Income
-$105.5M
Profit Margin
0%
SRRK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$535.3M
Liabilities
$259.2M
Debt to equity
0.94
SRRK's short-term assets ($515.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SRRK's short-term assets ($515.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SRRK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SRRK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$82.1M
Investing
-$5.3M
Financing
$193.8M
SRRK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SRRK vs Biotech Stocks
Scholar Rock Holding Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.